Clinical trials: Vehicle
Hypercholesterolemia, Heterozygous Familial
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Primary objective: Determine whether mipomersen (ISIS 301012) significantly reduces atherogenic lipid levels in patients with severe heterozygous familial hypercholesterolemia (severe HeFH), defined as low-density lipoprotein…
- Trial name
- FOCUS FH (NCT01475825)
- Testing
- mipomersen sodium 200 mg, mipomersen sodium 70 mg
- Where
- 113 sites in United States, Argentina and 28 more
- Volunteers
- 309 people
- Sponsor
- Kastle Therapeutics, LLC
Neurotrophic Keratitis
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm.
- Trial name
- NCT04909450
- Testing
- CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
- Where
- 48 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Claris Biotherapeutics, Inc.
Inflammation and Pain Associated With Cataract Surgery
2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation and pain associated with cataract surgery.
- Trial name
- ISV-305 (NCT03192150)
- Testing
- ISV-305, Vehicle
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Acne Vulgaris
Efficacy Study in Patients With Acne Vulgaris.
Safety and efficacy study in patients with acne vulgaris
- Trial name
- NCT02935036
- Testing
- ADPS topical product
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Inflammation
Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement…
- Trial name
- NCT06164743
- Testing
- VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- VivaVision Biotech, Inc
Ocular Graft vs Host Disease, Dry Eye
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
The purpose of this study is to evaluate the tolerability and preliminary efficacy of rhDNase I eye drops in patients with ocular Graft-vs.-Host disease (oGVHD).
- Trial name
- NCT02702518
- Testing
- rhDNase I, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Illinois Chicago
Open-Angle Glaucoma, Ocular Hypertension
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), the primary objective is to demonstrate that the mean IOP reduction after 3 months of treatment with BOL-303259-X once daily (QD) is…
- Trial name
- LUNAR (NCT01749930)
- Testing
- BOL-303259-X, Timolol
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Bausch & Lomb Incorporated
Acne Vulgaris
P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne
This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.
- Trial name
- NCT02667444
- Testing
- SB204 4%, Vehicle Gel
- Where
- 55 sites in United States
- Volunteers
- 1,330 people
- Sponsor
- Novan, Inc.
Myasthenia Gravis
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.
- Trial name
- NCT02110706
- Testing
- Rituximab
- Where
- 26 sites in United States
- Volunteers
- 52 people
- Sponsor
- Yale University
Alopecia Areata
DPCP for the Treatment of Alopecia Areata
This is an open labeled study to determine the response and characteristics, safety and efficacy, of the proprietary DPCP ointment composition as a topical immunotherapeutic agent for the treatment of extensive alopecia areata.
- Trial name
- NCT03651752
- Testing
- Diphenylcyclopropenone (DPCP) Ointment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Minnesota
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.
Rosacea
A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea
The objectives of this study were to compare the safety and efficacy profiles of a generic Azelaic Acid Foam, 15% to the reference listed Finacea® (azelaic acid) Foam, 15% and to demonstrate therapeutic equivalence and safety of…
- Trial name
- NCT03287791
- Testing
- Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam
- Where
- 26 sites in United States
- Volunteers
- 924 people
- Sponsor
- Actavis Inc.
Bioavailability
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants.
- Trial name
- NCT05263921
- Testing
- PF-07321332/ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Drive, Recidivism
Intervention to Improve Driving Practices Among High-Risk Teen Drivers
The purpose of this study is to test the effects of an in-vehicle driving feedback technology, with and without parent communication training, on risky driving events, unsafe driving behaviors, and subsequent traffic violations…
- Conditions
- Drive, Recidivism, Communication, Feedback, Psychological
- Trial name
- projectDRIVE (NCT04317664)
- Testing
- In-vehicle device, Parent Communication
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Ginger Yang
Heart Arrest, Out-Of-Hospital
Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest
Phase II double blind (participants and investigator) placebo controlled randomized (1:1) clinical trial of inhaled nitric oxide (iNO) 20 ppm administered over 12h beginning as soon as possible but within 4 h of return of…
- Trial name
- iNOOHCA (NCT03079102)
- Testing
- Nitric Oxide, Nitrogen
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Cameron Dezfulian
Plaque Psoriasis
A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable…
- Trial name
- NCT02886702
- Testing
- Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%
- Where
- 30 sites in United States
- Volunteers
- 855 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Healthy
CC100: Safety and Tolerability of Single Doses
The purpose of this study is to see if CC100, given by mouth, is safe and is tolerated in increasing doses. How long the drug remains in the body will also be calculated.
- Trial name
- NCT02050334
- Testing
- CC100
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Chemigen, LLC
Allergic Conjunctivitis
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01551056
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Aciex Therapeutics, Inc.
Islet Cell Tumor
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
This study will estimate the treatment effect of everolimus in combination with pasireotide LAR relative to everolimus alone on progression-free survival (PFS) in patients with advanced progressive PNET.
- Trial name
- COOPERATE-2 (NCT01374451)
- Testing
- Everolimus, Pasireotide LAR
- Where
- 47 sites in United States, Argentina and 17 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
- Trial name
- NCT03761784
- Testing
- S6G5T-3, S6G5T-8
- Where
- United States
- Volunteers
- 424 people
- Sponsor
- Sol-Gel Technologies, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.